Evidence map›Paper›PMID 28231808›Full record

ArticleMolecular cancer2017

ITIH5 mediates epigenetic reprogramming of breast cancer cells.

Michael Rose, Vera Kloten, Erik Noetzel, Lukas Gola, Josef Ehling, Timon Heide, Steffen K Meurer, Aljona Gaiko-Shcherbak, Antonio S Sechi, Sebastian Huth and 10 more

Open access · goldAbstract read
In one paragraph

Article in Molecular cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 44 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. A biomechanical view of epigenetic tumor regulation.Journal of biological physics · 2023
    Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 2 countries.

Michael RoseInstitute of Pathology, Medical Faculty of the RWTH Aachen University, Aachen, Germany.
Vera KlotenInstitute of Pathology, Medical Faculty of the RWTH Aachen University, Aachen, Germany.
Erik NoetzelInstitute of Complex Systems, ICS-7: Biomechanics, Forschungszentrum Jülich GmbH, Jülich, Germany.
Lukas GolaInstitute of Pathology, Medical Faculty of the RWTH Aachen University, Aachen, Germany.
Josef EhlingDepartment of Experimental Molecular Imaging (ExMI), Helmholtz Institute for Biomedical Engineering, Medical Faculty of the RWTH Aachen University, Aachen, Germany.
Timon HeideInstitute of Pathology, Medical Faculty of the RWTH Aachen University, Aachen, Germany.
Steffen K MeurerExperimental Gene Therapy and Clinical Chemistry, Institute of Molecular Pathobiochemistry, Medical Faculty of the RWTH Aachen University, Aachen, Germany.
Aljona Gaiko-ShcherbakInstitute of Complex Systems, ICS-7: Biomechanics, Forschungszentrum Jülich GmbH, Jülich, Germany.
Antonio S SechiInstitute for Biomedical Engineering-Cell Biology, Medical Faculty of the RWTH Aachen University, Aachen, Germany.
Sebastian HuthInstitute of Pathology, Medical Faculty of the RWTH Aachen University, Aachen, Germany.
Ralf WeiskirchenExperimental Gene Therapy and Clinical Chemistry, Institute of Molecular Pathobiochemistry, Medical Faculty of the RWTH Aachen University, Aachen, Germany.
Oliver KlaasInstitute of Pathology, Medical Faculty of the RWTH Aachen University, Aachen, Germany.
Wiebke AntonopoulosInstitute of Pathology, Medical Faculty of the RWTH Aachen University, Aachen, Germany.
Qiong LinInstitute for Biomedical Engineering-Cell Biology, Medical Faculty of the RWTH Aachen University, Aachen, Germany.
Wolfgang WagnerInstitute for Biomedical Engineering-Cell Biology, Medical Faculty of the RWTH Aachen University, Aachen, Germany.
Jürgen VeeckInstitute of Pathology, Medical Faculty of the RWTH Aachen University, Aachen, Germany.
Felix GremseDepartment of Experimental Molecular Imaging (ExMI), Helmholtz Institute for Biomedical Engineering, Medical Faculty of the RWTH Aachen University, Aachen, Germany.
Julia SteitzInstitute for Laboratory Animal Science, Medical Faculty of the RWTH Aachen University, Aachen, Germany.
Ruth KnüchelInstitute of Pathology, Medical Faculty of the RWTH Aachen University, Aachen, Germany.
Edgar DahlInstitute of Pathology, Medical Faculty of the RWTH Aachen University, Aachen, Germany. edahl@ukaachen.de.
RWTH Aachen University · DEForschungszentrum Jülich · DEMaastricht University Medical Centre · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundExtracellular matrix (ECM) is known to maintain epithelial integrity. In carcinogenesis ECM degradation triggers metastasis by controlling migration and differentiation including cancer stem cell (CSC) characteristics. The ECM-modulator inter- α-trypsin inhibitor heavy chain family member five (ITIH5) was recently identified as tumor suppressor potentially involved in impairing breast cancer progression but molecular mechanisms underlying its function are still elusive.

methodsITIH5 expression was analyzed using the public TCGA portal. ITIH5-overexpressing single-cell clones were established based on T47D and MDA-MB-231 cell lines. Colony formation, growth, apoptosis, migration, matrix adhesion, traction force analyses and polarization of tumor cells were studied in vitro. Tumor-initiating characteristics were analyzed by generating a metastasis mouse model. To identify ITIH5-affected pathways we utilized genome wide gene expression and DNA methylation profiles. RNA-interference targeting the ITIH5-downstream regulated gene DAPK1 was used to confirm functional involvement.

resultsITIH5 loss was pronounced in breast cancer subtypes with unfavorable prognosis like basal-type tumors. Functionally, cell and colony formation was impaired after ITIH5 re-expression in both cell lines. In a metastasis mouse model, ITIH5 expressing MDA-MB-231 cells almost completely failed to initiate lung metastases. In these metastatic cells ITIH5 modulated cell-matrix adhesion dynamics and altered biomechanical cues. The profile of integrin receptors was shifted towards β1-integrin accompanied by decreased Rac1 and increased RhoA activity in ITIH5-expressing clones while cell polarization and single-cell migration was impaired. Instead ITIH5 expression triggered the formation of epithelial-like cell clusters that underwent an epigenetic reprogramming. 214 promoter regions potentially marked with either H3K4 and /or H3K27 methylation showed a hyper- or hypomethylated DNA configuration due to ITIH5 expression finally leading to re-expression of the tumor suppressor DAPK1. In turn, RNAi-mediated knockdown of DAPK1 in ITIH5-expressing MDA-MB-231 single-cell clones clearly restored cell motility.

conclusionsOur results provide evidence that ITIH5 triggers a reprogramming of breast cancer cells with known stem CSC properties towards an epithelial-like phenotype through global epigenetic changes effecting known tumor suppressor genes like DAPK1. Therewith, ITIH5 may represent an ECM modulator in epithelial breast tissue mediating suppression of tumor initiating cancer cell characteristics which are thought being responsible for the metastasis of breast cancer.

Indexed as

DNA MethylationAnimalsBreast NeoplasmsCell Line, TumorDeath-Associated Protein KinasesEpigenesis, GeneticExtracellular MatrixFemaleGene Expression Regulation, NeoplasticHumansLung NeoplasmsMiceNeoplasm TransplantationPrognosisProteinase Inhibitory Proteins, SecretorySurvival AnalysisDAPK1 protein, humanDeath-Associated Protein KinasesITIH5 protein, humanProteinase Inhibitory Proteins, SecretoryBreast cancerCancer stem cellsDAPK1Epigenetic reprogrammingExtracellular matrixITIH5

Identifiers

PMID28231808
PMCPMC5322623
OpenAlexW2589739304

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.